Log In
BCIQ
Print this Print this
 

Imlygic, T-Vec, talimogene laherparepvec

Also known as: formerly OncoVEX GM-CSF

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionModified herpes simplex virus type 1 (HSV-1) carrying the gene for GM-CSF
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentMarketed
Standard IndicationMelanoma
Indication DetailsLocal treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma that is recurrent after initial surgery; Treat advanced melanoma; Treat melanoma; Treat metastatic melanoma
Regulatory Designation U.S. - Special Protocol Assessment (Treat metastatic melanoma);
U.S. - Standard Review (Treat metastatic melanoma);
EU - Standard Review (Treat metastatic melanoma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1,000.0M

$425.0M

$575.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today